Figure 2 | Scientific Reports

Figure 2

From: A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax

Figure 2

Cfz and Mzb but no Ixz overcome resistance to Btz. (a) Cells were treated with Cfz (n = 2) and Mzb (n = 2) for 1 h, and Alamar Blue assay was performed 48 h later. Cells were treated with Ixz continuously (n = 4) because Ixz is reversible and persists in patient blood much longer than other inhibitors44,45. The numbers on the graphs are p-values. Continuous treatment with Cfz also reversed resistance (Fig. S1d). (b,c) Inhibition of each active site was measured with Proteasome-Glo immediately after 1 h treatment and overlayed on viability data from (a), (b) or Fig. 1b (c); n = 2.

Back to article page